|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
|
|
|
|||||||||
|
|||||||||||
|
J Am Coll Cardiol, 2004; 44:1587-1592, doi:10.1016/j.jacc.2004.06.072 © 2004 by the American College of Cardiology Foundation |
,*
* Division of Cardiology, University of Alberta, Edmonton, Canada
Division of General Internal Medicine, University of Alberta, Edmonton, Canada
|| Division of Nephrology, University of Alberta, Edmonton, Canada
Division of Cardiology, University of British Columbia, Vancouver, Canada
Faculty of Nursing, University of Alberta, Edmonton, Canada
¶ Division of General Internal Medicine, University of Calgary, Calgary, Canada
# Division of Cardiology, University of Calgary, Calgary, Canada
Manuscript received March 1, 2004; revised manuscript received June 15, 2004, accepted June 22, 2004.
* Reprint requests and correspondence: Dr. Finlay A. McAlister, 2E3.24 WMC, University of Alberta Hospital, 8440 112th Street, Edmonton, Alberta, Canada T6G 2R7 (Email: Finlay.McAlister{at}ualberta.ca).
OBJECTIVES: This study was designed to examine the use of cardiovascular medications and outcomes in patients with heart failure (HF) and renal dysfunction.
BACKGROUND: Renal insufficiency is associated with poorer outcomes in patients with HF, but the mechanisms are uncertain. In particular, the degree of therapeutic nihilism in these patients, and whether it is appropriate, is unclear.
METHODS: This was a prospective cohort study with a one-year follow-up.
RESULTS: In 6,427 patients with cardiologist-diagnosed HF and angiographically proven coronary artery disease (mean age 69 years; 65% men; one-year mortality, 10%), 39% had creatinine clearances <60 ml/min. Patients with renal insufficiency were less likely to be prescribed angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, statins, or aspirin (all p < 0.001). However, users of aspirin (odds ratio [OR] 0.69, 95% confidence interval [CI] 0.57 to 0.85), statins (OR 0.79, 95% CI 0.64 to 0.97), and beta-blockers (OR 0.75, 95% CI 0.62 to 0.90) were less likely to die in the subsequent 12 months than nonusers, irrespective of renal function (all OR adjusted for covariates including atherosclerotic burden and ejection fraction). Although ACE inhibitor users with creatinine clearances 
60 ml/min had lower 12-month mortality (OR 0.72, 95% CI 0.48 to 0.99), ACE inhibitor users with clearances <60 ml/min did not (OR 1.21, 95% CI 0.97 to 1.51).
CONCLUSIONS: Renal insufficiency is common in patients with HF and coronary artery disease, and these patients have more advanced coronary atherosclerosis. Patients with renal insufficiency are less likely to be prescribed efficacious therapies, but have better outcomes if they receive these medications.
| ||||||||
This article has been cited by other articles:
|
|
 |
|
  W. A. K. M. Windt, R. H. Henning, A. C. A. Kluppel, Y. Xu, D. de Zeeuw, and R. P. E. van Dokkum Myocardial infarction does not further impair renal damage in 5/6 nephrectomized rats Nephrol. Dial. Transplant., June 4, 2008; (2008) gfn233v2. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Patwardhan, D. B. Matchar, G. P. Samsa, and W. E. Haley Opportunities for Improving Management of Advanced Chronic Kidney Disease American Journal of Medical Quality, June 1, 2008; 23(3): 184 - 192. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Tonelli, F. Sacks, M. Arnold, L. Moye, B. Davis, M. Pfeffer, and for the Cholesterol and Recurrent Events (CARE) Tr Relation Between Red Blood Cell Distribution Width and Cardiovascular Event Rate in People With Coronary Disease Circulation, January 15, 2008; 117(2): 163 - 168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Authors/Task Force Members, I. Graham, D. Atar, K. Borch-Johnsen, G. Boysen, G. Burell, R. Cifkova, J. Dallongeville, G. De Backer, S. Ebrahim, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts) Eur. Heart J., October 1, 2007; 28(19): 2375 - 2414. [Full Text] [PDF]
|
|
|
|
 |
|
 D. T Eurich, F. A McAlister, D. F Blackburn, S. R Majumdar, R. T Tsuyuki, J. Varney, and J. A Johnson Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review BMJ, September 8, 2007; 335(7618): 497 - 497. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Chonchol, V. Aboyans, P. Lacroix, G. Smits, T. Berl, and M. Laskar Long-term outcomes after coronary artery bypass grafting: Preoperative kidney function is prognostic J. Thorac. Cardiovasc. Surg., September 1, 2007; 134(3): 683 - 689. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. G. Glynn, D. Reddan, J. Newell, J. Hinde, B. Buckley, and A. W. Murphy Chronic kidney disease and mortality and morbidity among patients with established cardiovascular disease: a West of Ireland community-based cohort study Nephrol. Dial. Transplant., September 1, 2007; 22(9): 2586 - 2594. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. C Lang and D. M Mancini Non-cardiac comorbidities in chronic heart failure Heart, June 1, 2007; 93(6): 665 - 671. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. A. McAlister, A. Oreopoulos, C. M. Norris, M. M. Graham, R. T. Tsuyuki, M. Knudtson, W. A. Ghali, and for the Alberta Provincial Project for Outcome Ass Exploring the Treatment-Risk Paradox in Coronary Disease Arch Intern Med, May 28, 2007; 167(10): 1019 - 1025. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. A.K.M. Windt, W. B.A. Eijkelkamp, R. H. Henning, A. C.A. Kluppel, P. A. de Graeff, H. L. Hillege, S. Schafer, D. de Zeeuw, and R. P.E. van Dokkum Renal Damage after Myocardial Infarction Is Prevented by Renin-Angiotensin-Aldosterone-System Intervention J. Am. Soc. Nephrol., November 1, 2006; 17(11): 3059 - 3066. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. I. Parikh, S.-J. Hwang, M. G. Larson, J. B. Meigs, D. Levy, and C. S. Fox Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control. Arch Intern Med, September 25, 2006; 166(17): 1884 - 1891. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Coca, H. M. Krumholz, A. X. Garg, and C. R. Parikh Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA, September 20, 2006; 296(11): 1377 - 1384. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Tonelli, N. Wiebe, B. Culleton, A. House, C. Rabbat, M. Fok, F. McAlister, and A. X. Garg Chronic Kidney Disease and Mortality Risk: A Systematic Review J. Am. Soc. Nephrol., July 1, 2006; 17(7): 2034 - 2047. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. A. McAlister, W. A. Ghali, Y. Gong, J. Fang, P. W. Armstrong, and J. V. Tu Aspirin Use and Outcomes in a Community-Based Cohort of 7352 Patients Discharged After First Hospitalization for Heart Failure Circulation, June 6, 2006; 113(22): 2572 - 2578. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. L. Smith, J. H. Lichtman, M. B. Bracken, M. G. Shlipak, C. O. Phillips, P. DiCapua, and H. M. Krumholz Renal Impairment and Outcomes in Heart Failure: Systematic Review and Meta-Analysis J. Am. Coll. Cardiol., May 16, 2006; 47(10): 1987 - 1996. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Segura, J. A. Garcia-Donaire, M. Praga, and L. M. Ruilope Chronic Kidney Disease as a Situation of High Added Risk in Hypertensive Patients J. Am. Soc. Nephrol., April 1, 2006; 17(4_suppl_2): S136 - S140. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Tonelli, A. Keech, J. Shepherd, F. Sacks, A. Tonkin, C. Packard, M. Pfeffer, J. Simes, C. Isles, C. Furberg, et al. Effect of Pravastatin in People with Diabetes and Chronic Kidney Disease J. Am. Soc. Nephrol., December 1, 2005; 16(12): 3748 - 3754. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. T. Eurich, S. R. Majumdar, F. A. McAlister, R. T. Tsuyuki, and J. A. Johnson Improved Clinical Outcomes Associated With Metformin in Patients With Diabetes and Heart Failure Diabetes Care, October 1, 2005; 28(10): 2345 - 2351. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Tonelli, C. Isles, T. Craven, A. Tonkin, M. A. Pfeffer, J. Shepherd, F. M. Sacks, C. Furberg, S. M. Cobbe, J. Simes, et al. Effect of Pravastatin on Rate of Kidney Function Loss in People With or at Risk for Coronary Disease Circulation, July 12, 2005; 112(2): 171 - 178. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. D.J. Smilde, H. L. Hillege, D. J. van Veldhuisen, and G. Navis Angiotensin-Converting Enzyme Inhibitors and Outcome Among Patients With Heart Failure and Renal Insufficiency: Need for a Prospective Study J. Am. Coll. Cardiol., June 7, 2005; 45(11): 1905 - 1905. [Full Text] [PDF]
|
|
|
|
|
|
J.-P. Bassand, S. Priori, and M. Tendera Evidence-based vs. 'impressionist' medicine: how best to implement guidelines Eur. Heart J., June 2, 2005; 26(12): 1155 - 1158. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Which Drug Therapies Prevent Death in Patients with CAD, Heart Failure, and Renal Insufficiency? Journal Watch Cardiology, December 3, 2004; 2004(1203): 3 - 3. [Full Text]
|
|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
